Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

OpGen to Provide Business Update and Financial Results for the First Quarter 2021 onáMay 13th at 8:30 a.m. Eastern Time

04/29/2021 | 07:30am EDT

GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021. OpGen’s management team will host a live conference call and audio webcast at 8:30 a.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
U.S. Dial-in Number:
International Dial-in Number:
Webcast:
Conference ID:
+1 (877) 705 6003
+1 (201) 493 6725
http://public.viavid.com/index.php?id=144749
13719409
  
Replay Details
U.S. Dial-in Number:
International Dial-in Number:
Replay PIN:
+1 (844) 512 2921
+1 (412) 317 6671
13719409

Following the conclusion of the conference call, a replay will be available through May 27, 2021. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website under Financials & Filings.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Megan Paul
Edison Group
mpaul@edisongroup.com


Primary Logo


ę GlobeNewswire 2021
All news about OPGEN, INC.
08/03OPGEN : Corporate Presentation (PDF)
PU
08/03OPGEN : Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
AQ
07/30SUPERNUS PHARMACEUTICALS : Pharma Says Named New CFO After Incumbent Resigned to..
MT
07/29OPGEN INC : Change in Directors or Principal Officers (form 8-K)
AQ
07/29Opgen, Inc. Announces Resignation of Timothy C. Dec as Corporate Secretary, E..
CI
07/07OPGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/07OpGen Announces Partial Adjournment of Annual Meeting
GL
06/30OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AM..
GL
06/28OpGen Group Company Ares Genetics Presents R&D Pipeline Updates
GL
06/25OPGEN, INC.(NASDAQCM : OPGN) dropped from Russell Microcap Growth Index
CI
More news
Financials (USD)
Sales 2021 7,79 M - -
Net income 2021 -35,6 M - -
Net Debt 2021 3,78 M - -
P/E ratio 2021 -2,44x
Yield 2021 -
Capitalization 91,8 M 91,8 M -
EV / Sales 2021 12,3x
EV / Sales 2022 5,05x
Nbr of Employees 102
Free-Float 99,8%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 2,40 $
Average target price 5,50 $
Spread / Average Target 129%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.17.65%92
MODERNA, INC.231.78%139 174
LONZA GROUP AG25.60%58 688
IQVIA HOLDINGS INC.39.52%47 386
CELLTRION, INC.-26.18%31 285
SEAGEN INC.-9.68%28 062